Synta announces results from ganetespib Phase 2b trial on NSCLC

[News]

Synta Pharmaceuticals Corp. today announced results from an interim analysis of the Phase 2b portion of the GALAXY trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the efficacy and safety of the Company's lead Hsp90 inhibitor, ganetespib, as second-line treatment for advanced non-small cell lung cancer (NSCLC).

More... (http://www.news-medical.net/news/20120929/Synta-announces-results-from-ganetespib-Phase-2b-trial-on-NSCLC.aspx)